8-K/A: Sensei Biotherapeutics Files Amendment to 8-K

Sensei Biotherapeutics amends prior 8-K filing to include audited financial statements of acquired Faeth Subsidiary and pro forma combined financial information.

Summary

• This filing is an amendment (Amendment No. 1) to a previous Form 8-K report filed on February 18, 2026.
• The amendment's primary purpose is to update Item 9.01 of the original report.
• Specifically, it adds the audited consolidated financial statements for Faeth Subsidiary (formerly Faeth Therapeutics, Inc.) for the years ended December 31, 2025, and 2024.
• It also includes unaudited pro forma condensed combined financial information for Sensei Biotherapeutics, Inc. as of and for the year ended December 31, 2025.
• This amendment does not alter any other sections of the original report or discuss events after the original filing date.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it is an amendment to correct and supplement previous disclosures rather than announcing new material events or performance metrics.

Positives

• The filing provides updated and complete financial statements for the acquired entity, Faeth Subsidiary, which is crucial for understanding the combined entity's financial position.
• Inclusion of pro forma combined financial information offers a clearer picture of the potential financial performance of Sensei Biotherapeutics post-acquisition.

Negatives

• The filing itself is an amendment, indicating that the original report was incomplete, requiring a subsequent filing to provide necessary financial data.
• The financial statements of Faeth Therapeutics, Inc. (Exhibit 99.3) indicate substantial doubt about its ability to continue as a going concern due to potential significant cash payments related to Series B Preferred Stock conversion, although this is mitigated by the acquisition and PIPE financing.

Risks

• Substantial doubt about Faeth Therapeutics, Inc.'s ability to continue as a going concern due to potential significant cash payments related to Series B Preferred Stock conversion, as noted in the independent auditors' report.
• The pro forma financial information is preliminary and subject to revision, meaning actual results could differ materially.
• The combined company's ability to satisfy potential cash settlement obligations related to Series B Preferred Stock conversion is contingent on stockholder approval and timely delivery of common stock.

Future Outlook

The filing itself is an amendment to a prior report and does not contain new forward-looking statements or guidance. It focuses on providing historical financial data and pro forma combined information related to a past acquisition.

Industry Context

StockSavvy.ai notes that this amendment highlights the critical importance of comprehensive financial disclosures following significant corporate events like acquisitions. The inclusion of audited financials for the acquired entity and pro forma data is standard practice to provide investors with a clearer, albeit retrospective, view of the combined business's financial standing.

Stakeholder Impact

• Shareholders: The amendment provides more complete financial information, aiding in their assessment of the acquisition's impact and the combined entity's financial health.
• Investors: The pro forma financial information is crucial for investors evaluating the potential of the combined company.
• Creditors: Updated financial statements offer a clearer view of the combined entity's liabilities and financial stability.

Next Steps

• The company will need to ensure that the Parent Stockholder Matters are approved by stockholders to facilitate the conversion of Series B Preferred Stock into Common Stock.
• Final accounting and integration of Faeth's financial data into Sensei Biotherapeutics' reporting will be ongoing.

Key Dates

Keywords

SEC Filing, 8-K/A, Amendment, Financial Statements, Pro Forma, Acquisition, Faeth Therapeutics, Sensei Biotherapeutics